Ó£»¨ÊÓƵ

Skip to main content

Table 2 Prevalence of neck and low back pain by gender in the general Chinese population aged 45Ìýyears and above

From: The prevalence and factors associated with neck and low back pain in patients with stroke: insights from the CHARLS

Ìý

Non-stroke Neck pain

Non-stroke Low back pain

Overall

Female

Male

Overall

Female

Male

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

Ìý

16,197

17.80%(17.21–18.39)

8567

23.43%(22.53–24.32)

7630

11.48%(10.77–12.20)

16,197

37.22%(36.47–37.96)

8567

43.75%(42.70–44.80)

7630

29.88%(28.85–30.91)

Age, years

 45–54

4270

18.03%(16.88–19.19)

2401

42.40%(40.42–44.38)

1869

29.59%(27.52–31.66)

4270

36.79%(35.34–38.24)

2401

42.40%(40.42–44.38)

1869

29.59%(27.52–31.66)

 55–64

5535

18.68%(17.65–19.71)

2880

42.92%(41.11–44.73)

2655

30.02%(28.27–31.76)

5535

36.73%(35.46–38.00)

2880

42.92%(41.11–44.73)

2655

30.02%(28.27–31.76)

 65–74

4332

17.84%(16.70–18.98)

2211

45.77%(43.69–47.85)

2121

30.08%(28.13–32.03)

4332

38.09%(36.64–39.54)

2211

45.77%(43.69–47.85)

2121

30.08%(28.13–32.03)

 ≥ 75

2060

14.85%(13.32–16.39)

1075

44.84%(41.86–47.81)

985

29.64%(26.79–32.50)

2060

37.57%(35.48–39.67)

1075

44.84%(41.86–47.81)

985

29.64%(26.79–32.50)

 p value

Ìý

0.002

Ìý

0.079

Ìý

0.983

Ìý

0.491

Ìý

0.079

Ìý

0.983

Residence

‼۳ܰù²¹±ô

12,424

17.85%(17.18–18.53)

6575

45.23%(44.03–46.44)

5849

31.49%(30.30–32.68)

12,424

38.76%(37.91–39.62)

6575

45.23%(44.03–46.44)

5849

31.49%(30.30–32.68)

 u°ù²ú²¹²Ô

3773

17.63%(16.41–18.84)

1992

38.86%(36.71–41.00)

1781

24.59%(22.59–26.59)

3773

32.12%(30.63–33.61)

1992

38.86%(36.71–41.00)

1781

24.59%(22.59–26.59)

 p value

Ìý

0.749

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Education

 i±ô±ô¾±³Ù±ð°ù²¹³Ù±ð

3795

20.66%(19.37–21.95)

3024

45.21%(43.43–46.98)

771

33.07%(29.75–36.40)

3795

42.74%(41.17–44.32)

3024

45.21%(43.43–46.98)

771

33.07%(29.75–36.40)

 elementary school or below

6982

18.30%(17.40–19.21)

3440

45.64%(43.97–47.30)

3542

32.92%(31.37–34.47)

6982

39.19%(38.04–40.33)

3440

45.64%(43.97–47.30)

3542

32.92%(31.37–34.47)

 secondary school and above

5420

15.15%(14.19–16.10)

2103

38.56%(36.48–40.65)

3317

25.90%(24.41–27.39)

5420

30.81%(29.58–32.04)

2103

38.56%(36.48–40.65)

3317

25.90%(24.41–27.39)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Disability

 n´Ç

14,356

16.50%(15.89–17.11)

7590

42.00%(40.89–43.11)

6766

28.26%(27.19–29.33)

14,356

35.53%(34.74–36.31)

7590

42.00%(40.89–43.11)

6766

28.26%(27.19–29.33)

 y±ð²õ

1841

27.92%(25.87–29.97)

977

57.32%(54.21–60.43)

864

42.59%(39.29–45.90)

1841

50.41%(48.12–52.69)

977

57.32%(54.21–60.43)

864

42.59%(39.29–45.90)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Chronic Disease

 0

9643

14.03%(13.34–14.72)

5044

37.67%(36.33–39.01)

4599

25.20%(23.95–26.46)

9643

31.72%(30.79–32.65)

5044

37.67%(36.33–39.01)

4599

25.20%(23.95–26.46)

 1

4355

20.48%(19.28–21.68)

2315

50.19%(48.16–52.23)

2040

34.02%(31.96–36.08)

4355

42.62%(41.15–44.09)

2315

50.19%(48.16–52.23)

2040

34.02%(31.96–36.08)

 2

2199

29.01%(27.11–30.91)

1208

56.79%(53.99–59.59)

991

43.09%(40.00–46.18)

2199

50.61%(48.52–52.71)

1208

56.79%(53.99–59.59)

991

43.09%(40.00–46.18)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Sleep Time

 ≤ 6 h

8838

22.22%(21.36–23.09)

4952

49.41%(48.02–50.81)

3886

34.82%(33.32–36.32)

8838

43.00%(41.96–44.03)

4952

49.41%(48.02–50.81)

3886

34.82%(33.32–36.32)

 6-8Ìýh

5821

12.61%(11.76–13.46)

2799

36.26%(34.48–38.05)

3022

24.95%(23.41–26.49)

5821

30.39%(29.21–31.57)

2799

36.26%(34.48–38.05)

3022

24.95%(23.41–26.49)

 ≥ 8 h

1538

12.03%(10.40–13.66)

816

35.05%(31.77–38.33)

722

23.96%(20.84–27.08)

1538

29.84%(27.55–32.13)

816

35.05%(31.77–38.33)

722

23.96%(20.84–27.08)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Nap Time

 ≤ 30 min

9039

19.04%(18.23–19.85)

5185

45.36%(44.01–46.72)

3854

31.16%(29.70–32.63)

9039

39.31%(38.30–40.31)

5185

45.36%(44.01–46.72)

3854

31.16%(29.70–32.63)

 31-60Ìýmin

4087

17.37%(16.21–18.53)

1995

42.16%(39.99–44.32)

2092

28.06%(26.13–29.99)

4087

34.94%(33.48–36.40)

1995

42.16%(39.99–44.32)

2092

28.06%(26.13–29.99)

 ≥ 61 min

3071

14.72%(13.46–15.97)

1387

40.01%(37.43–42.60)

1684

29.22%(27.04–31.39)

3071

34.09%(32.42–35.77)

1387

40.01%(37.43–42.60)

1684

29.22%(27.04–31.39)

 p value

Ìý

0

Ìý

0.001

Ìý

0.035

Ìý

0

Ìý

0.001

Ìý

0.035

Dyspraxia

 n´Ç

4986

7.44%(6.71–8.17)

1903

19.65%(17.87–21.44)

3083

16.67%(15.36–17.99)

4986

17.81%(16.75–18.87)

1903

19.65%(17.87–21.44)

3083

16.67%(15.36–17.99)

 y±ð²õ

11,211

22.41%(21.63–23.18)

6664

50.63%(49.43–51.83)

4547

38.84%(37.42–40.26)

11,211

45.85%(44.93–46.77)

6664

50.63%(49.43–51.83)

4547

38.84%(37.42–40.26)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Depressive

 n´Ç

10,762

12.70%(12.07–13.33)

5170

35.16%(33.86–36.47)

5592

24.46%(23.34–25.59)

10,762

29.60%(28.74–30.47)

5170

35.16%(33.86–36.47)

5592

24.46%(23.34–25.59)

 y±ð²õ

5435

27.89%(26.70–29.09)

3397

56.81%(55.15–58.48)

2038

44.75%(42.59–46.91)

5435

52.29%(50.96–53.62)

3397

56.81%(55.15–58.48)

2038

44.75%(42.59–46.91)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Drink

 n´Ç

10,683

19.67%(18.91–20.42)

7362

43.10%(41.97–44.23)

3321

30.08%(28.52–31.64)

10,683

39.05%(38.13–39.98)

7362

43.10%(41.97–44.23)

3321

30.08%(28.52–31.64)

 y±ð²õ

5514

14.18%(13.26–15.10)

1205

47.72%(44.89–50.54)

4309

29.73%(28.36–31.09)

5514

33.66%(32.41–34.91)

1205

47.72%(44.89–50.54)

4309

29.73%(28.36–31.09)

 p value

Ìý

0

Ìý

0.003

Ìý

0.739

Ìý

0

Ìý

0.003

Ìý

0.739

ADL

 n´Ç

13,397

14.50%(13.90–15.09)

6780

38.19%(37.03–39.34)

6617

26.82%(25.76–27.89)

13,397

32.57%(31.78–33.37)

6780

38.19%(37.03–39.34)

6617

26.82%(25.76–27.89)

 y±ð²õ

2800

33.61%(31.86–35.36)

1787

64.86%(62.64–67.07)

1013

49.85%(46.77–52.94)

2800

59.43%(57.61–61.25)

1787

64.86%(62.64–67.07)

1013

49.85%(46.77–52.94)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

ADL_ins

 n´Ç

12,561

14.44%(13.83–15.06)

6205

37.60%(36.39–38.80)

6356

26.83%(25.74–27.91)

12,561

32.15%(31.33–32.96)

6205

37.60%(36.39–38.80)

6356

26.83%(25.74–27.91)

 y±ð²õ

3636

29.40%(27.92–30.88)

2362

59.91%(57.93–61.88)

1274

45.13%(42.40–47.87)

3636

54.73%(53.11–56.35)

2362

59.91%(57.93–61.88)

1274

45.13%(42.40–47.87)

 p value

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Activity_intensive

 less than 10Ìýmin

10,895

17.66%(16.94–18.38)

6223

41.68%(40.46–42.91)

4672

26.84%(25.57–28.11)

10,895

35.32%(34.42–36.22)

6223

41.68%(40.46–42.91)

4672

26.84%(25.57–28.11)

 More than 10Ìýmin

5302

18.09%(17.05–19.12)

2344

49.23%(47.21–51.26)

2958

34.69%(32.97–36.40)

5302

41.12%(39.79–42.44)

2344

49.23%(47.21–51.26)

2958

34.69%(32.97–36.40)

 p value

Ìý

0.504

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Activity_moderate

 less than 10Ìýmin

8146

15.39%(14.61–16.18)

3882

41.19%(39.64–42.74)

4264

28.68%(27.32–30.04)

8146

34.64%(33.61–35.68)

3882

41.19%(39.64–42.74)

4264

28.68%(27.32–30.04)

 More than 10Ìýmin

8051

20.23%(19.36–21.11)

4685

45.87%(44.44–47.30)

3366

31.40%(29.83–32.97)

8051

39.82%(38.75–40.89)

4685

45.87%(44.44–47.30)

3366

31.40%(29.83–32.97)

 p value

Ìý

0

Ìý

0

Ìý

0.001

Ìý

0

Ìý

0

Ìý

0.01

Activity_light

 less than 10Ìýmin

2769

16.90%(15.50–18.30)

1479

44.62%(42.09–47.16)

1290

27.83%(25.38–30.28)

2769

36.80%(35.00–38.60)

1479

44.62%(42.09–47.16)

1290

27.83%(25.38–30.28)

 More than 10Ìýmin

13,428

17.98%(17.34–18.63)

7088

43.57%(42.41–44.72)

6340

30.30%(29.17–31.43)

13,428

37.30%(36.48–38.12)

7088

43.57%(42.41–44.72)

6340

30.30%(29.17–31.43)

 p value

Ìý

0.175

Ìý

0.456

Ìý

0.077

Ìý

0.619

Ìý

0.456

Ìý

0.077

Treatments for Stroke

 n´Ç

16,197

Ìý

8567

Ìý

7630

Ìý

16,197

Ìý

8567

Ìý

7630

Ìý

 y±ð²õ

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

0

Ìý

 p value

ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý
Ìý

Stroke Neck pain

Stroke Low back pain

Overall

Female

Male

Overall

Female

Male

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

n

Prevalence (95%CI)

Ìý

885

26.44% (23.53–29.35)

457

33.70%(29.35–38.05)

428

18.69%(14.98–22.40)

885

45.42% (42.14–48.71)

457

57.33%(52.78–61.88)

428

32.71%(28.25–37.17)

Age, years

 45–54

82

29.27%(19.21–39.33)

40

40%(24.13–55.87)

42

19.05%(6.66–31.43)

82

47.56%(36.52–58.60)

40

55%(38.89–71.13)

42

40.48%(24.99–55.96)

 55–64

260

25%(19.70–30.30)

126

30.95%(22.77–39.14)

134

19.40%(12.62–26.19)

260

46.15%(40.05–52.25)

126

61.11%(52.48–69.74)

134

32.09%(24.08–40.10)

 65–74

351

28.77%(24.02–33.53)

196

35.71%(28.95–42.48)

155

20%(13.63–26.37)

351

45.58%(40.35–50.82)

196

57.65%(50.67–64.63)

155

30.32%(23.01–37.64)

 ≥ 75

192

22.92%(16.92–28.92)

95

30.53%(21.10–39.96)

97

15.46%(8.14–22.79)

192

43.23%(36.16–50.30)

95

52.63%(42.41–62.86)

97

34.02%(24.42–43.62)

 p value

Ìý

0.421

Ìý

0.591

Ìý

0.83

Ìý

0.901

Ìý

0.641

Ìý

0.65

Residence

‼۳ܰù²¹±ô

653

26.19%(22.81–29.57)

338

32.84%(27.81–37.87)

315

19.05%(14.69–23.41)

653

46.40%(42.57–50.24)

338

57.69%(52.40–62.99)

315

34.29%(29.02–39.56)

 u°ù²ú²¹²Ô

232

27.16%(21.39–32.92)

119

36.13%(27.38–44.89)

113

17.70%(10.55–24.84)

232

42.67%(36.26–49.08)

119

56.30%(47.26–65.34)

113

28.32%(19.88–36.75)

 p value

Ìý

0.774

Ìý

0.514

Ìý

0.753

Ìý

0.328

Ìý

0.793

Ìý

0.247

Education

 i±ô±ô¾±³Ù±ð°ù²¹³Ù±ð

245

28.98%(23.26–34.70)

185

29.73%(23.08–36.38)

60

26.67%(15.15–38.19)

245

53.47%(47.18–59.76)

185

58.38%(51.21–65.55)

60

38.33%(25.67–51.00)

 elementary school or below

379

31.40%(26.70–36.09)

190

40%(32.97–47.03)

189

22.75%(16.72–28.78)

379

49.34%(44.28–54.40)

190

61.05%(54.06–68.05)

189

37.57%(30.60–44.53)

 secondary school and above

261

16.86%(12.29–21.43)

82

28.05%(18.12–37.98)

179

11.73(6.97–16.49)

261

32.18%(26.48–37.89)

82

46.34%(35.32–57.37)

179

25.70%(19.24–32.16)

 p value

Ìý

0

Ìý

0.054

Ìý

0.006

Ìý

0

Ìý

0.074

Ìý

0.032

Disability

 n´Ç

628

24.84%(21.45–28.23)

325

31.69%(26.61–36.78)

303

17.49%(13.19–21.79)

628

44.11%(40.21–48.00)

325

55.08%(49.64–60.51)

303

32.34%(27.05–37.64)

 y±ð²õ

257

30.35%(24.69–36.01)

132

38.64%(30.22–47.05)

125

21.60%(14.29–28.91)

257

48.64%(42.49–54.79)

132

62.88%(54.53–71.22)

125

33.60%(25.20–42.00)

 p value

Ìý

0.092

Ìý

0.155

Ìý

0.323

Ìý

0.22

Ìý

0.127

Ìý

0.802

Chronic Disease

 0

350

21.43%(17.11–25.75)

177

29.38%(22.60–36.15)

173

13.29%(8.18–18.40)

350

38.57%(33.45–43.70)

177

53.11%(45.68–60.53)

173

23.70%(17.30–30.10)

 1

282

26.60%(21.41–31.78)

146

34.93%(27.11–42.76)

136

17.65%(11.16–24.14)

282

43.97%(38.14–49.80)

146

54.11%(45.93–62.29)

136

33.09%(25.08–41.10)

 2

253

33.20%(27.36–39.04)

134

38.06%(29.73–46.39)

119

27.73%(19.57–35.89)

253

56.52%(50.37–62.67)

134

66.42%(58.32–74.52)

119

45.38%(36.30–54.45)

 p value

Ìý

0.005

Ìý

0.258

Ìý

0.007

Ìý

0

Ìý

0.04

Ìý

0.001

Sleep Time

 ≤ 6 h

509

33.99%(29.86–38.12)

289

41.87%(36.15–47.59)

220

23.64%(17.98–29.29)

509

50.29%(45.93–54.65)

289

59.86%(54.18–65.55)

220

37.73%(31.27–44.18)

 6-8Ìýh

275

16.36%(11.96–20.76)

126

20.63%(13.47–27.80)

149

12.75%(7.33–18.17)

275

38.18%(32.40–43.96)

126

52.38%(43.54–61.22)

149

26.17%(19.03–33.31)

 ≥ 8 h

101

15.84%(8.60–23.09)

42

16.67%(4.91–28.42)

59

15.25%(5.80–24.70)

101

40.59%(30.85–50.33)

42

54.76%(39.06–70.46)

59

30.51%(18.41–42.61)

 p value

Ìý

0

Ìý

0

Ìý

0.024

Ìý

0.003

Ìý

0.346

Ìý

0.063

Nap Time

 ≤ 30 min

455

30.11%(25.88–34.34)

258

36.82%(30.90–42.75)

197

21.32%(15.55–27.09)

455

49.67%(45.06–54.28)

258

58.53%(52.48–64.58)

197

38.07%(31.23–44.91)

 31-60Ìýmin

200

19.50%(13.96–25.04)

102

26.47%(17.76–35.18)

98

12.24%(5.64–18.85)

200

44.00%(37.06–50.94)

102

62.75%(53.20–72.29)

98

24.49%(15.82–33.16)

 ≥ 61 min

230

25.22%(19.56–30.87)

97

32.99%(23.46–42.52)

133

19.55%(12.72–26.38)

230

38.26%(31.93–44.59)

97

48.45%(38.33–58.58)

133

30.83%(22.88–38.78)

 p value

Ìý

0.016

Ìý

0.172

Ìý

0.163

Ìý

0.016

Ìý

0.106

Ìý

0.055

Dyspraxia

 n´Ç

104

10.58%(4.57–16.59)

26

11.54%(-1.62–24.70)

78

10.26%(3.37–17.14)

104

18.27%(10.72–25.82)

26

26.92%(8.65–45.19)

78

15.38%(7.20–23.57)

 y±ð²õ

781

28.55%(25.38–31.73)

431

35.03%(30.51–39.56)

350

20.57%(16.32–24.83)

781

49.04%(45.53–52.55)

431

59.16%(54.51–63.82)

350

36.57%(31.50–41.64)

 p value

Ìý

0

Ìý

0.014

Ìý

0.035

Ìý

0

Ìý

0.001

Ìý

0

Depressive

 n´Ç

506

19.76%(16.28–23.24)

231

24.68%(19.07–30.28)

275

15.64%(11.32–19.96)

506

35.57%(31.39–39.76)

231

45.89%(39.41–52.36)

275

26.91%(21.63–32.18)

 y±ð²õ

379

35.36%(30.52–40.19)

226

42..92%(36.42–49.42)

153

24.18%(17.32–31.04)

379

58.58%(53.59–63.56)

226

69.03%(62.95–75.10)

153

43.14%(35.20–51.07)

 p value

Ìý

0

Ìý

0

Ìý

0.03

Ìý

0

Ìý

0

Ìý

0.001

Drink

 n´Ç

683

28.26%(24.87–31.64)

417

32.85%(28.33–37.38)

266

21.05%(16.12–25.98)

683

46.71%(42.95–50.46)

417

55.88%(51.09–60.67)

266

32.33%(26.67–37.99)

 y±ð²õ

202

20.30%(14.70–25.89)

40

42.50%(26.49–58.51)

162

14.81%(9.29–20.34)

202

41.09%(34.25–47.93)

40

72.50%(58.04–86.96)

162

33.33%(26.00–40.67)

 p value

Ìý

0.024

Ìý

0.219

Ìý

0.109

Ìý

0.159

Ìý

0.042

Ìý

0.831

ADL

 n´Ç

508

21.85%(18.24–25.46)

229

30.57%(24.56–36.58)

279

14.70%(10.52–18.88)

508

39.57%(35.30–43.83)

229

55.46%(48.97–61.94)

279

26.52%(21.31–31.74)

 y±ð²õ

377

32.63%(27.87–37.38)

228

36.84%(30.53–43.15)

149

26.17%(19.03–33.31)

377

53.32%(48.26–58.37)

228

59.21%(52.78–65.64)

149

44.30%(36.23–52.36)

 p value

Ìý

0

Ìý

0.157

Ìý

0.004

Ìý

0

Ìý

0.419

Ìý

0

ADL_ins

 n´Ç

426

22.07%(18.11–26.02)

183

28.96%(22.33–35.60)

243

16.87%(12.13–21.61)

426

38.03%(33.40–42.66)

183

48.63%(41.32–55.94)

243

30.04%(24.24–35.85)

 y±ð²õ

459

30.50%(26.27–34.73)

274

36.86%(31.11–42.61)

185

21.08%(15.15–27.01)

459

52.29%(47.70–56.87)

274

63.14%(57.39–68.89)

185

36.22%(29.23–43.21)

 p value

Ìý

0.004

Ìý

0.08

Ìý

0.27

Ìý

0

Ìý

0.002

Ìý

0.178

Activity_intensive

 less than 10Ìýmin

705

25.11%(21.90–28.32)

376

31.91%(27.18–36.65)

329

17.33%(13.21–21.44)

705

43.55%(39.88–47.21)

376

55.32%(50.27–60.37)

329

30.09%(25.11–35.07)

 More than 10Ìýmin

180

31.67%(24.81–38.53)

81

41.98%(30.99–52.96)

99

23.23%(14.77–31.70)

180

52.78%(45.41–60.14)

81

66.67%(56.18–77.16)

99

41.41%(31.54–51.29)

 p value

Ìý

0.075

Ìý

0.083

Ìý

0.187

Ìý

0.15

Ìý

0.061

Ìý

0.035

Activity_moderate

 less than 10Ìýmin

559

24.87%(21.27–28.46)

267

31.84%(26.21–37.46)

292

18.49%(14.01–22.97)

559

42.75%(38.64–46.87)

267

55.81%(49.81–61.80)

292

30.82%(25.49–36.15)

 More than 10Ìýmin

326

29.14%(24.18–34.10)

190

36.32%(29.42–43.22)

136

19.12%(12.42–25.81)

326

50%(44.54–55.46)

190

59.47%(52.43–66.52)

136

36.76%(28.56–44.97)

 p value

Ìý

0.165

Ìý

0.319

Ìý

0.878

Ìý

0.037

Ìý

0.436

Ìý

0.223

Activity_light

 less than 10Ìýmin

211

24.17%(18.35–29.99)

132

28.03%(20.27–35.79)

79

17.72%(9.11–26.33)

211

47.39%(40.60–54.19)

132

54.55%(45.94–63.15)

79

35.44%(24.66–46.23)

 More than 10Ìýmin

674

27.15%(23.79–30.52)

325

36%(30.75–41.25)

349

18.91%(14.78–23.04)

674

44.81%(41.04–48.57)

325

58.46%(53.08–63.85)

349

32.09%(27.17–37.01)

 p value

Ìý

0.392

Ìý

0.103

Ìý

0.807

Ìý

0.511

Ìý

0.444

Ìý

0.568

Treatments for Stroke

 n´Ç

232

22.41%(17.01–27.82)

124

29.84%(21.67–38.01)

108

13.89%(7.26–20.52)

232

43.10%(36.68–49.52)

124

52.42%(43.51–61.33)

108

32.41%(23.44–41.38)

 y±ð²õ

653

27.87%(24.42–31.32)

333

35.14%(29.98–40.29)

320

20.31%(15.88–24.74)

653

46.25%(42.41–50.08)

333

59.16%(53.85–64.47)

320

32.81%(27.64–37.98)

 p value

Ìý

0.106

Ìý

0.288

Ìý

0.139

Ìý

0.409

Ìý

0.196

Ìý

0.938

  1. One-way ANOVA was used to compare the differences in prevalence rates between different groups, with the test level α = 0.05, and p < 0.05 indicating that the differences were statistically significant